Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients

Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients

Gallium-68 labeled prostate-specific membrane antigen (Ga-68 PSMA) ligand (HBED-CC) is a novel tracer used for prostate cancer imaging. The aim of the study was to investigate the performance of Ga-68 PSMA positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurre...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aravintho Natarajan, Archi Agrawal, Vedang Murthy, Ganesh Bakshi, Amit Joshi, Nilendu Purandare, Sneha Shah, Ameya Puranik, Venkatesh Rangarajan
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-07-01
Series:	World Journal of Nuclear Medicine
Subjects:	biochemical failure biochemical recurrence gallium-68 prostate-specific membrane antigen positron emission tomography prostate cancer
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_47_18
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
by: Marcus Edward Asokendaran, et al.
Published: (2019-07-01)

Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography
by: Manoj Gupta, et al.
Published: (2021-03-01)

False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography
by: Sofiullah Abubakar, et al.
Published: (2018-10-01)

Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography studies for treatment response assessment in prostate cancer
by: Ismet Sarikaya, et al.
Published: (2018-07-01)

68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for prostate cancer imaging: A narrative literature review
by: Jose Oliveira, et al.
Published: (2017-01-01)

Neuroendocrine prostate cancer or prostatitis? An unusual false positive on gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography in a patient with known metastatic neuroendocrine tumor
by: Matthew Q Schmidt, et al.
Published: (2019-07-01)

Can gallium-68 prostate-specific membrane antigen ligand be a potential radiotracer for renal cortical positron emission tomography imaging?
by: Ismet Sarikaya, et al.
Published: (2018-04-01)

A case of hepatic focal nodular hyperplasia mimicking hepatocellular carcinoma identified on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography
by: Seckin Bilgic, et al.
Published: (2021-04-01)

A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience
by: Manoj Gupta, et al.
Published: (2017-07-01)

High Detection Rates for Prostate-specific Membrane Antigen–avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography
by: Sarah Thomas, et al.
Published: (2025-01-01)

Indications and Results for Ga-68 PSMA PET/CT in Patients with Biochemical Relapse of Prostate Cancer
by: Ivan Rogić, et al.
Published: (2024-01-01)

Fibrous dysplasia as a possible false-positive finding in 68Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography study in the follow-up of prostate cancer
by: André Marcondes Braga Ribeiro, et al.
Published: (2019-10-01)

Extrapleural solitary fibrous tumor evidenced by 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography study in the staging of a high-risk prostate cancer patient
by: André Braga Ribeiro, et al.
Published: (2020-10-01)

Whole-Body Bone Scan for Detecting Bone Metastasis in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era: A Retrospective Cohort Study of Post-Radical Prostatectomy Prostate Cancer Patients
by: Chanikarn Poenateetai, et al.
Published: (2025-07-01)

Four rare extranodal sites seen on FDG PET/CT in a single patient of disseminated lymphoma
by: Ameya D Puranik, et al.
Published: (2013-01-01)

Secondary Analysis of PSA and BCR-Free Survival in Asian Prostate Cancer Patients
by: Gao X, et al.
Published: (2025-06-01)

A comparison of routine [68Ga]Ga-PSMA-11 preparation using Locametz and Illuccix kits
by: Ivan E. Wang, et al.
Published: (2024-12-01)

Testing the diagnostic accuracy of a 68Ga-PSMA PET Scan in Early Biochemical Recurrence of Prostate Cancer
by: Vigna-Taglianti Riccardo, et al.
Published: (2024-10-01)

The value of post radiotherapy prostate specific antigen dynamics for prostate cancer risk stratification models
by: Jane Shortall, et al.
Published: (2025-04-01)

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents
by: Ute Hennrich, et al.
Published: (2025-06-01)

Isolated aplasia of submandibular salivary gland and contralateral prominence of submandibular and sublingual salivary glands incidentally found on 68Ga-prostate-specific membrane antigen positron emission tomography—computed tomography
by: Abbas Yousefi-Koma, et al.
Published: (2020-07-01)

Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review
by: Nigel P. Murray
Published: (2025-05-01)

Construction and validation of a lysine beta hydroxybutyrylation related molecular model for predicting biochemical recurrence of prostate cancer
by: Desheng Zhu, et al.
Published: (2025-08-01)

Understanding the Impact of Salvage Radiation on the Long‐Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
by: Spyridon P. Basourakos, et al.
Published: (2025-07-01)

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer
by: Karen A. Autio, et al.
Published: (2025-04-01)

Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review
by: Soroush Rais-Bahrami, et al.
Published: (2025-05-01)

Unexpected discovery of hepatic cancer via 68Ga-PSMA PET/CT in the staging of prostate cancer
by: Radu Alexa, et al.
Published: (2025-06-01)

The older the better: The characteristic of localized prostate cancer in Chinese men
by: Haifeng Wang, et al.
Published: (2015-07-01)

PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy
by: Ruohua Chen, et al.
Published: (2025-07-01)

Preclinical Evaluation of a Novel PSMA-Targeted Agent <sup>68</sup>Ga-NOTA-GC-PSMA for Prostate Cancer Imaging
by: Wenjin Li, et al.
Published: (2025-03-01)

How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View
by: Daniela E. Oprea-Lager, et al.
Published: (2025-05-01)

Positron emission tomography in mucosal melanomas of head and neck: Results from a South Asian tertiary cancer care center
by: Archi Agrawal, et al.
Published: (2017-07-01)

Prognostic role and therapeutic implications of phosphatidylinositol transfer protein cytoplasmic 1 in primary prostate cancer
by: Jianming Lu, et al.
Published: (2024-11-01)

Biochemical Recurrence in High-Risk Localized Prostate Cancer: A Comparison of Laparoscopic Prostatectomy and External Radiotherapy
by: Lubos Rybar, et al.
Published: (2025-05-01)

THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER
by: Duygu Has Şimşek, et al.
Published: (2021-01-01)

Enhancing Prostate Cancer Detection: Integrating Multiparametric Magnetic Resonance Imaging and 68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography with Machine Learning
by: Mohammad Hossein Sadeghi, et al.
Published: (2025-04-01)

Prostate-specific antigen cutoff value for ordering sodium fluoride positron emission tomography/computed tomography bone scan in patients with prostate cancer
by: Ismet Sarikaya, et al.
Published: (2018-10-01)

Prognostic significance of the logistic regression model for assessing the risk of recurrence in patients with prostate cancer after radical prostatectomy
by: S. A. Reva, et al.
Published: (2022-12-01)

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes
by: Dietrich Pfeiffer, et al.
Published: (2015-01-01)